283 related articles for article (PubMed ID: 34884723)
1. Combined Blockade of TIGIT and CD39 or A2AR Enhances NK-92 Cell-Mediated Cytotoxicity in AML.
Brauneck F; Seubert E; Wellbrock J; Schulze Zur Wiesch J; Duan Y; Magnus T; Bokemeyer C; Koch-Nolte F; Menzel S; Fiedler W
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884723
[TBL] [Abstract][Full Text] [Related]
2. Increased frequency of TIGIT
Brauneck F; Haag F; Woost R; Wildner N; Tolosa E; Rissiek A; Vohwinkel G; Wellbrock J; Bokemeyer C; Schulze Zur Wiesch J; Ackermann C; Fiedler W
Oncoimmunology; 2021 Jun; 10(1):1930391. PubMed ID: 34211801
[TBL] [Abstract][Full Text] [Related]
3. Increased TIGIT expressing NK cells with dysfunctional phenotype in AML patients correlated with poor prognosis.
Liu G; Zhang Q; Yang J; Li X; Xian L; Li W; Lin T; Cheng J; Lin Q; Xu X; Li Q; Lin Y; Zhou M; Shen E
Cancer Immunol Immunother; 2022 Feb; 71(2):277-287. PubMed ID: 34129052
[TBL] [Abstract][Full Text] [Related]
4. Terminal differentiation of bone marrow NK cells and increased circulation of TIGIT
Zeng X; Yao D; Liu L; Zhang Y; Lai J; Zhong J; Zha X; Lu Y; Jin Z; Chen S; Li Y; Xu L
Asia Pac J Clin Oncol; 2022 Aug; 18(4):456-464. PubMed ID: 34811925
[TBL] [Abstract][Full Text] [Related]
5. The co-inhibitory receptor TIGIT regulates NK cell function and is upregulated in human intrahepatic CD56
Ziegler AE; Fittje P; Müller LM; Ahrenstorf AE; Hagemann K; Hagen SH; Hess LU; Niehrs A; Poch T; Ravichandran G; Löbl SM; Padoan B; Brias S; Hennesen J; Richard M; Richert L; Peine S; Oldhafer KJ; Fischer L; Schramm C; Martrus G; Bunders MJ; Altfeld M; Lunemann S
Front Immunol; 2023; 14():1117320. PubMed ID: 36845105
[TBL] [Abstract][Full Text] [Related]
6. CD56brightCD16- NK Cells Produce Adenosine through a CD38-Mediated Pathway and Act as Regulatory Cells Inhibiting Autologous CD4+ T Cell Proliferation.
Morandi F; Horenstein AL; Chillemi A; Quarona V; Chiesa S; Imperatori A; Zanellato S; Mortara L; Gattorno M; Pistoia V; Malavasi F
J Immunol; 2015 Aug; 195(3):965-72. PubMed ID: 26091716
[TBL] [Abstract][Full Text] [Related]
7. Increased Expression of TIGIT/CD57 in Peripheral Blood/Bone Marrow NK Cells in Patients with Chronic Myeloid Leukemia.
Yao D; Xu L; Liu L; Zeng X; Zhong J; Lai J; Zheng R; Jin Z; Chen S; Zha X; Huang X; Lu Y
Biomed Res Int; 2020; 2020():9531549. PubMed ID: 33102599
[TBL] [Abstract][Full Text] [Related]
8. Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma.
Brauneck F; Weimer P; Schulze Zur Wiesch J; Weisel K; Leypoldt L; Vohwinkel G; Fritzsche B; Bokemeyer C; Wellbrock J; Fiedler W
Front Med (Lausanne); 2021; 8():763773. PubMed ID: 34820398
[No Abstract] [Full Text] [Related]
9. A2AR limits IL-15-induced generation of CD39
Kang G; Zhao X; Sun J; Cheng C; Wang C; Tao L; Zong L; Yin W; Cong J; Li J; Wang X
Int Immunopharmacol; 2023 Jan; 114():109567. PubMed ID: 36529024
[TBL] [Abstract][Full Text] [Related]
10. CD56
Vujanovic L; Chuckran C; Lin Y; Ding F; Sander CA; Santos PM; Lohr J; Mashadi-Hossein A; Warren S; White A; Huang A; Kirkwood JM; Butterfield LH
Front Immunol; 2019; 10():14. PubMed ID: 30761123
[TBL] [Abstract][Full Text] [Related]
11. [Percentages and functions of natural killer cell subsets in peripheral blood of patients with severe aplastic anemia].
Li ZS; Shao ZH; Fu R; Wang J; Li LJ; Zhang T; Wang HQ; Wu YH; Ruan EB; Song J; Qu W; Liu H; Xing LM; Wang XM; Liang Y; Guan J; Wang GJ
Zhonghua Yi Xue Za Zhi; 2011 Apr; 91(16):1084-7. PubMed ID: 21609587
[TBL] [Abstract][Full Text] [Related]
12. DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy.
Sanchez-Correa B; Valhondo I; Hassouneh F; Lopez-Sejas N; Pera A; Bergua JM; Arcos MJ; Bañas H; Casas-Avilés I; Durán E; Alonso C; Solana R; Tarazona R
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31234588
[TBL] [Abstract][Full Text] [Related]
13. TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer.
Maas RJ; Hoogstad-van Evert JS; Van der Meer JM; Mekers V; Rezaeifard S; Korman AJ; de Jonge PK; Cany J; Woestenenk R; Schaap NP; Massuger LF; Jansen JH; Hobo W; Dolstra H
Oncoimmunology; 2020 Nov; 9(1):1843247. PubMed ID: 33224630
[TBL] [Abstract][Full Text] [Related]
14. PVRIG is a novel natural killer cell immune checkpoint receptor in acute myeloid leukemia.
Li J; Whelan S; Kotturi MF; Meyran D; D'Souza C; Hansen K; Liang S; Hunter J; Trapani JA; Neeson PJ
Haematologica; 2021 Dec; 106(12):3115-3124. PubMed ID: 33147937
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint markers and anti-CD20-mediated NK cell activation.
Wang Z; Weiner GJ
J Leukoc Biol; 2021 Oct; 110(4):723-733. PubMed ID: 33615552
[TBL] [Abstract][Full Text] [Related]
16. IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma.
Chauvin JM; Ka M; Pagliano O; Menna C; Ding Q; DeBlasio R; Sanders C; Hou J; Li XY; Ferrone S; Davar D; Kirkwood JM; Johnston RJ; Korman AJ; Smyth MJ; Zarour HM
Clin Cancer Res; 2020 Oct; 26(20):5520-5533. PubMed ID: 32591463
[TBL] [Abstract][Full Text] [Related]
17. [The Expression and Function of NK Cells in Patients with Acute Myeloid Leukemia].
Liu L; Chen X; Jin HM; Zhao SS; Zhu Y; Qian SX; Wu YJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):49-55. PubMed ID: 35123603
[TBL] [Abstract][Full Text] [Related]
18. Increased number of CD16(+)CD56(dim) NK cells in peripheral blood mononuclear cells after allogeneic cord blood transplantation.
Tanaka J; Sugita J; Asanuma S; Arita K; Shono Y; Kikutchi M; Shiratori S; Wakasa K; Yasumoto A; Shigematu A; Kondo T; Kobayashi T; Asaka M; Imamura M
Hum Immunol; 2009 Sep; 70(9):701-5. PubMed ID: 19524005
[TBL] [Abstract][Full Text] [Related]
19. NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance.
Martner A; Rydström A; Riise RE; Aurelius J; Brune M; Foà R; Hellstrand K; Thorén FB
Oncotarget; 2015 Dec; 6(40):42569-74. PubMed ID: 26544512
[TBL] [Abstract][Full Text] [Related]
20. Natural Killer Cell Subpopulations and Inhibitory Receptor Dynamics in Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Cianga VA; Campos Catafal L; Cianga P; Pavel Tanasa M; Cherry M; Collet P; Tavernier E; Guyotat D; Rusu C; Aanei CM
Front Immunol; 2021; 12():665541. PubMed ID: 33986753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
